Literature DB >> 20471669

Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.

Beata Kwasny-Krochin1, Piotr Gluszko, Anetta Undas.   

Abstract

OBJECTIVE: Altered fibrin clot properties have been reported in cardiovascular diseases (CVD) and inflammatory states. Given increased prevalence of CVD in patients with rheumatoid arthritis (RA), we investigated whether fibrin characteristics are also altered in RA patients. PATIENTS AND METHODS: We studied 46 consecutive RA patients versus 50 controls matched for age and gender. Ex vivo plasma clot permeability, turbidity, tissue-type plasminogen activator (tPA)-induced fibrinolysis, and scanning electron microscopy (SEM) images of clots were evaluated.
RESULTS: Patients with RA had lower clot permeability, faster clot formation, higher maximum clot absorbency indicating thicker fibrin fibers, maximum clot mass and prolonged fibrinolysis time than controls. Maximum rates of clot lysis were similar in both groups. SEM images showed formation of dense clots with many projections on fibrin fibers. Clot permeability inversely correlated with fibrinogen, tPA, plasminogen activator inhibitor-1 (PAI-1), CRP, platelet count, disease activity score (DAS28) and a marker of oxidative stress, 8-iso-prostaglandin F2alpha (r from -0.44 to -0.79; all, p<0.0001). Similar positive associations were found for clot lysis time (r 0.44 to 0.69; all, p<0.01). Multiple regression analysis showed that fibrinogen was the only independent predictor of clot permeability (R2=0.87, p<0.0001) and lysis time (R2=0.80, p<0.003) in RA. Maximum D-dimer levels released from clots, maximum clot turbidity and the time of clot formation were predicted by PAI-1 (all, p<0.05).
CONCLUSION: We showed unfavorably altered plasma fibrin clot structure and function in RA, which might contribute to an increased risk of thrombotic events in this disease. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471669     DOI: 10.1016/j.thromres.2010.04.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  15 in total

1.  Assessment of hemostatic disturbances in women with established rheumatoid arthritis.

Authors:  Aleksandra Vranic; Iva Pruner; Mirjana Veselinovic; Nida Soutari; Anica Petkovic; Vladimir Jakovljevic; Aleksandra Antovic
Journal:  Clin Rheumatol       Date:  2019-06-17       Impact factor: 2.980

2.  Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability.

Authors:  Rami Abu-Fanne; Victoria Stepanova; Rustem I Litvinov; Suhair Abdeen; Khalil Bdeir; Mohamed Higazi; Emad Maraga; Chandrasekaran Nagaswami; Alexander R Mukhitov; John W Weisel; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Blood       Date:  2018-11-15       Impact factor: 22.113

3.  Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion.

Authors:  Harini Raghu; Carolina Cruz; Cheryl L Rewerts; Malinda D Frederick; Sherry Thornton; Eric S Mullins; Jonathan G Schoenecker; Jay L Degen; Matthew J Flick
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

4.  Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.

Authors:  Rodney D Averett; David G Norton; Natalie K Fan; Manu O Platt
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

5.  Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.

Authors:  Florian Posch; Stefanie Hofer; Johannes Thaler; Lena Hell; Oliver Königsbrügge; Ella Grilz; Lisa-Marie Mauracher; Johanna Gebhart; Christine Marosi; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  Transl Res       Date:  2019-08-29       Impact factor: 7.012

6.  The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile.

Authors:  Lize Bollen; Niels Vande Casteele; Miet Peeters; Gert Van Assche; Marc Ferrante; Wouter Van Moerkercke; Paul Declerck; Séverine Vermeire; Ann Gils
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

7.  Prevalence of Cognitive Impairment in Recently Diagnosed Type 2 Diabetes Patients: Are Chronic Inflammatory Diseases Responsible for Cognitive Decline?

Authors:  Pilar Lavielle; Juan O Talavera; Nancy Reynoso; Marissa González; Rita A Gómez-Díaz; Miguel Cruz; Felipe Vázquez; Niels H Wacher
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

8.  Determinants of hypofibrinolysis in patients with digestive tract cancer.

Authors:  Katarzyna Gronostaj; Piotr Richter; Wojciech Nowak; Anetta Undas
Journal:  Prz Gastroenterol       Date:  2016-02-02

Review 9.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

10.  Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia.

Authors:  Lucyna Mastalerz; Magdalena Celińska-Lӧwenhoff; Piotr Krawiec; Bogdan Batko; Witold Tłustochowicz; Anetta Undas
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.